DMB-3113

Meiji Seika Pharma Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	DMB-3113
Sponsor	Meiji Seika Pharma Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DMB-3113 CI brief — competitive landscape report
DMB-3113 updates RSS · CI watch RSS
Meiji Seika Pharma Co., Ltd. portfolio CI